Table 1.
Selected characteristics of participants enrolled in Rostam and crude and weighted prevalence of chronic HCV infection, with row percentages as a proportion of the total enrolled.
| Characteristics | Total (%) | HCV chronic infection | |
|---|---|---|---|
| Crude n (%) |
Weighted n (%) |
||
| N= 171 | 47 (27.5%) | 47 (23.5%) | |
| Age (years) | |||
| Median (IQR) | 39 (34, 47) | 42 (38, 50) | 42 (38, 50) |
| 18–29 | 18 (10.5) | 3 (16.7) | 3 (18.0) |
| 30–39 | 69 (40.3) | 15 (21.7) | 15 (24.3) |
| ≥40 | 84 (49.2) | 29 (34.5) | 29 (30.2) |
| Sex | |||
| Male | 153 (89.5) | 44 (28.7) | 44 (32.3) |
| Female | 18 (10.5) | 3 (16.7) | 3 (13.1) |
| Education | |||
| Primary or less | 61 (35.7) | 16 (26.2) | 16 (20.3) |
| Some or completed secondary or high school | 96 (56.1) | 27 (28.1) | 27 (39.0) |
| University | 14 (8.2) | 4 (28.6) | 4 (23.6) |
| Unemployed, current | |||
| Yes | 38 (22.2) | 12 (31.6) | 12 (30.1) |
| No | 133 (77.8) | 35 (26.3) | 35 (28.0) |
| Monthly incomea | |||
| Under 1,000,000T (<$100) | 127 (75.1) | 39 (30.7) | 39 (36.4) |
| 1,000,000–4,999,999T ($100–499) | 39 (23.1) | 7 (17.9) | 7 (11.9) |
| 5,000,000T or more (>$500) | 3 (1.8) | - | - |
| Living with their spouse/partner, current | |||
| Yes (i.e., married, live with partners) | 24 (14.1) | 5 (20.8) | 5 (17.4) |
| No (i.e., single, married but live alone, widowed) | 147 (85.9) | 42 (28.6) | 42 (32.0) |
| Homelessness, evera | |||
| Yes | 150 (88.2) | 38 (25.3) | 38 (30.8) |
| No | 20 (11.8) | 9 (45.0) | 9 (39.5) |
| Incarceration, the last 12 months | |||
| Yes | 42 (24.5) | 9 (21.4) | 9 (19.4) |
| No | 129 (75.5) | 38 (29.5) | 38 (31.5) |
| Any alcohol use, the last 12 monthsa | |||
| Yes | 41 (24.4) | 15 (36.6) | 15 (31.4) |
| No | 127 (75.6) | 32 (25.2) | 32 (30.4) |
| HIV status | |||
| Positive | 6 (3.5) | 6 (100.0) | 6 (100.0) |
| Negative | 165 (96.5) | 41 (24.8) | 41 (17.4) |
| Years since first injection | |||
| Median (IQR) | 27 (22, 33) | 24 (22, 31) | 24 (22.31) |
| Injecting frequency, the last 3 monthsa | |||
| Daily | 57 (33.5) | 22 (38.6) | 22 (31.7) |
| Weekly (i.e. Not daily but at least weekly) | 36 (21.2) | 9 (25.0) | 9 (23.8) |
| Less than weekly | 53 (31.2) | 10 (18.9) | 10 (9.7) |
| None | 24 (14.1) | 6 (25.0) | 6 (42.2) |
| Injected with another person, the last 12 monthsa | |||
| Yes | 119 (70.0) | 37 (31.1) | 37 (38.2) |
| No | 51 (30.0) | 10 (19.6) | 10 (23.5) |
| Receptive syringe sharing, the last 12 months | |||
| Yes | 13 (7.6) | 3 (23.1) | 3 (20.7) |
| No | 158 (92.4) | 44 (27.8) | 44 (30.1) |
| Receptive injecting equipment sharing, the last 12 months | |||
| Yes | 26 (15.2) | 14 (53.8) | 14 (55.5) |
| No | 145 (84.8) | 33 (22.7) | 33 (21.1) |
| Drug overdose, evera | |||
| Yes | 73 (42.9) | 24 (32.9) | 24 (34.6) |
| No | 97 (57.1) | 23 (23.7) | 23 (25.4) |
| Received OAT, last 12 months | |||
| Yes | 160 (93.6) | 44 (27.5) | 44 (29.8) |
| No | 11 (6.4) | 3 (27.3) | 3 (25.0) |
| Easy access to free needle/syringe, currenta | |||
| Yes (very easy/somehow easy) | 112 (69.6) | 34 (30.3) | 34 (33.2) |
| No (very difficult/somehow difficult) | 49 (30.4) | 13 (26.5) | 13 (23.6) |
| HCV testing, evera,b | |||
| Yes | 20 (11.8) | 11 (55.0) | 11 (57.6) |
| No | 133 (78.7) | 32 (24.1) | 32 (22.5) |
| Do not know | 16 (9.5) | 4 (25.0) | 4 (24.0) |
| HCV treatment uptake, evera,b,c | |||
| Yes | 5 (45.5) | 3 (60.0) | 3 (61.0) |
| No | 6 (54.5) | 5 (83.3) | 5 (80.0) |
a
Among participants with available information
b
Self-reported
c
Among 11 individuals who reported ever being HCV RNA positive
Abbreviations- IQR; interquartile range, OAT; opioid agonist therapy